News | June 03, 2022
CMP Pharma announces calcium channel blocker ‘Norliqva’ availability
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Subscribe To Our Newsletter & Stay Updated
